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A B S T R A C T
Group C Rotavirus (RVC) has been associated globally with sporadic outbreaks of gastroenteritis in children and
adults. RVC also infects animals, and interspecies transmission has been reported as well as its zoonotic po-
tential. Considering its genetic diversity and the absence of effective vaccines, it is important and necessary to
develop new generation vaccines against RVC for both humans and animals. The aim of the present study was to
develop and characterize an HSV-1-based amplicon vector expressing a human RVC-VP6 protein and evaluate
the humoral immune response induced after immunizing BALB/c mice. Local fecal samples positive for RVC
were used for isolation and sequencing of the vp6 gene, which phylogenetically belongs to the I2 genotype. We
show here that cells infected with the HSV[VP6C] amplicon vector efficiently express the VP6 protein, and
induced specific anti-RVC antibodies in mice immunized with HSV[VP6C], in a prime-boost schedule. This work
highlights that amplicon vectors are an attractive platform for the generation of safe genetic immunogens against
RVC, without the addition of external adjuvants.
1. Introduction
Rotaviruses (RV), an important genus of the Reoviridae family, are
responsible for most viral diarrhea cases occurring in young humans
and animals. These viruses have been classified into different groups
based on the antigenic properties or the amino acid sequences of the
structural protein VP6 (Estes and Greenberg, 2013), although a full
genome-based classification has been proposed recently (Matthijnssens
et al., 2008; Patton, 2012). With regards to VP6-based classification,
eight groups of RV have been defined (A to H) (Matthijnssens et al.,
2012).
Rotaviruses from groups A, B, C, and H have been associated with
human infections, with group A being the most epidemiologically im-
portant worldwide (Patton, 2012). Fortunately, the two currently li-
censed vaccines prevent severe diarrhea associated with group A RV
(RVA) reducing its impact and mortality rates, even considering a
variable efficacy in developing countries (Bucardo and Nordgren, 2015;
Karafillakis et al., 2015).
Group C RV (RVC) has been demonstrated to contribute to sporadic
outbreaks and endemic gastroenteritis in children older than those in-
fected with RVA (4–7 years) and adults. However, identification of RVC
has been less common than RVA. A possible cause might be associated
with the lack of simple diagnostic tools and the fact that it usually in-
fects older patients who, depending on the severity of clinical symp-
toms, do not necessarily attend to a medical care center where a correct
diagnosis can be made (Baek et al., 2013; Castello et al., 2009; Luchs
and do Carmo Sampaio Tavares Timenetsky, 2014; Tiku et al., 2017).
Different studies worldwide have demonstrated that the ser-
oprevalence for RVC is between 30 and 60%. Nevertheless, detection
rates in stool samples remain as low as 3% (Castello et al., 2009;
Ishimaru et al., 1990; Nilsson et al., 2000; Steele and James, 1999).
Particularly, in a study carried out over four years (1997-2000) in Ar-
gentina, half of the studied population had antibodies against RVC
(Castello et al., 2002). Although, neither the overall disease burden nor
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the epidemiology of this group of rotaviruses is yet entirely clear, RVC
infection has been described in numerous countries, showing epide-
miological importance as an emerging human pathogen (Araújo et al.,
2011; Castello et al., 2009; Luchs and do Carmo Sampaio Tavares
Timenetsky, 2014; Tiku et al., 2017).
The RVC mainly infects animals, being porcine species the most
frequently reported host (Vlasova et al., 2017; Wakuda et al., 2011),
although evidence of transmission was reported in Brazil, from infected
pigs to humans, suggesting a zoonotic potential for this virus (Gabbay
et al., 2008). Furthermore, the presence of RVC has been published
recently in companion animals, such as cats and dogs (Marton et al.,
2015b; Otto et al., 2015). Considering that interspecies transmission
events have been previously described (Chang et al., 1999; Jeong et al.,
2009), the emergence of RVC reassortants presenting higher infectivity
for humans cannot be underestimated (Marton et al., 2015a; Vlasova
et al., 2017).
Considering that there are few studies on this particular virus, it is
important to develop and analyze different strategies that can even-
tually be applied to immunize both humans and animals against RVC.
In this sense, a classical approach would be the immunization with
complete viral particles, whether inactivated or attenuated. However,
RVC has been difficult to propagate in cell culture (Saif et al., 1988;
Shinozaki et al., 1996; Tsunemitsu et al., 1991), impairing the devel-
opment of vaccines as well as diagnostic tools. Thus, alternatives that
can overcome this problem need to be addressed. To face this issue,
Clark et al., (2009) reported the generation of RVC VP6 virus-like
particles (VLP) using the baculovirus recombinant technology, which
efficiently induced specific antibody responses in rabbits. However,
there are some limitations associated with the baculovirus system,
which includes the need to use several purification steps and the rather
low quantity of correctly assembled VLP obtained from infected insect
cells (Kim et al., 2002; Peixoto et al., 2007).
In this sense, herpes simplex virus type 1 (HSV-1)-based vectors
represent an attractive gene delivery system, which has not been pre-
viously studied as a carrier for RVC antigenic sequences. HSV-1 am-
plicon vectors have a large transgene capacity (up to 150 kbp), which
allows the encapsidation of multiple genes or multiple copies of a
transgene. Moreover, these vectors present (i) low toxicity and im-
munogenicity, (ii) high in vivo transduction efficiencies, both in quies-
cent and proliferating cells from most mammalian species including
antigen presenting cells, (iii) genetic stability, and (iv) strong adjuvant
effects inducing both humoral and cellular immune responses as well as
mucosal immunity (de Silva and Bowers, 2009; Epstein, 2009;
Laimbacher and Fraefel et al., 2014).
In this work, the generation of an HSV-1 amplicon vector encoding
the VP6 protein from an Argentinean human RVC isolate and the
analysis of its immunogenic potential in mice is described.
2. Materials and methods
2.1. Viruses
Human stool samples (n= 2231) collected between 1997 and 2006
were screened for RVC and RVA using in-house developed enzyme
immunoassays (EIA) as previously described by Castello et al., (2000)
and Argüelles et al., (2000), respectively. Samples positive for RVC and
negative for RVA were selected for viral RNA extraction.
2.2. Genomic RNA extraction and cDNA synthesis
RVC positive fecal samples were diluted to 20% w/v in phosphate
buffered saline (PBS), and 100 μl of the obtained suspension were
mixed with 200 μl of Tris-HCl, 50mM pH 7.5, 300 μl of Vertrel XF®
(DuPont Chemicals, Wilmington, DE). After 1-min homogenization,
samples were sedimented by low-speed centrifugation. A 200 μl aliquot
of the aqueous phase was recovered and mixed with 400 μl of lysis
buffer (guanidine isothiocyanate 4M, EDTA 0.02M, Triton X-114
0.01% v/v) and 40 μl of a silica suspension (in HCl 0.1 N). After 15min
incubation at room temperature with constant stirring, the samples
were centrifuged for 1min at 580g, and the pellet washed first with
600 μl of a guanidine isothiocyanate 4M, EDTA 0.02M solution and
then washed three times with ethanol 70% v/v. After centrifugation at
9,280g for 2min, the supernatant was discarded, the pellet was dried
for 15min at room temperature, and the dsRNA was resuspended in
35 μl of sterile water. The sample was incubated for 10min at 65 °C,
centrifuged at 9,280g for 2min to remove the silica, and the super-
natant containing dsRNA was recovered and stored at -80 °C until fur-
ther use.
A 3-μl aliquot of the extracted dsRNA was used as the template for
reverse-transcription to synthesize cDNA copies from both strands.
Briefly, RNA was denatured at 95 °C for 5min and then incubated on ice
for 5min before this template was mixed with 22 μl of the reaction
mixture. The final mixture contained 500 μM of dNTPs (Promega, USA);
0.4 μM random primers; 7 U of AMV reverse transcriptase and 1X buffer
(Promega, USA); 20 U of RNasin RNase inhibitor (Promega, USA) and
5% v/v dimethyl sulfoxide (DMSO) in a final 25 μl volume. Synthesis of
the corresponding cDNA was performed for 2 h at 42 °C in a Biometra T
gradient thermocycler (Biometra GmbH, Germany).
2.3. Cloning of the human RVC VP6 coding sequence
Human RVC (hRVC) VP6 oligonucleotide primers were designed
based on reference RVC VP6 gene sequences, obtained from the
GenBank database. These primers were: Fwd-VP6-C1 5′-CTCATTCACA
ATGGATGTACT-3′ and Rev-VP6-C2 5′-CTAGCTTATCTACATTACC-3′.
The VP6 open reading frame was PCR amplified at the following con-
ditions: one cycle at 95 °C for 2min; 35 cycles of 94 °C for 10 s, 52 °C for
15 s, 72 °C for 90 s; and a final cycle at 72 °C for 10min.
The amplification product (1206 bp) was purified from the gel with
QIAquick Gel Extraction Kit (QIAGEN GmbH, Germany) and ligated
into pGEM-T (Promega, USA) according to the manufacturer's instruc-
tions. The ligation product was used to transform electrocompetent
TOP10 E. coli cells, as previously described (Sambrook et al., 1989).
Colony PCR screening was performed using the Fwd-VP6-C1 and Rev-
VP6-C2 primers, and positive clones were sent for sequencing (Mac-
rogen Inc., Seoul, South Korea).
2.4. VP6 phylogenetic analysis
Evolutionary relationships between previously reported human,
swine and bovine VP6 RVC sequences, and the one obtained in this
study were evaluated. Multiple sequence alignment was performed with
Clustal_X 2.1 software (Larkin et al., 2007), and phylogenetic analysis
was conducted using MEGA v6.06 (Tamura et al., 2013).
A phylogenetic dendrogram was constructed using nucleotide se-
quence alignments, by the neighbor-joining algorithm based on
Kimura-2 parameter distance matrix, with 1000 bootstrap replications.
Furthermore, the evolutionary divergence based on nucleotide and
amino acid sequences was also estimated. The analysis of the number of
base substitutions per site was conducted using the Maximum
Composite Likelihood model. Codon positions included were 1st+2nd
+3rd+Noncoding, and there was a total of 1123 positions in the final
dataset. The number of amino acid substitutions per site was analyzed
using the Poisson correction model. There was a total of 370 positions
in the final dataset. Both evolutionary analyses were conducted using
MEGA v6.06, and all positions containing gaps and missing data were
eliminated.
2.5. Nucleotide sequence accession number
The nucleotide sequence of the VP6 gene reported in this study was
submitted to GenBank, and the assigned accession number is
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MF422080.
2.6. Amplicon plasmid construction
Amplicon plasmid was constructed using the previously described
pHSVs system (D’Antuono et al., 2010; Laimbacher and Fraefel et al.,
2014). Briefly, the transgene expression is supported by the HSV-1 IE4/
5 promoter, followed by a viral internal ribosomal entry site (IRES)
which controls the EGFP reporter gene expression. The plasmid also
contains two HSV-1 functional sequences: the ori and the pac signal,
which support the replication of the amplicon DNA and packaging into
HSV-1 particles in the presence of HSV-1 helper functions. For pro-
karyotic propagation, the amplicon plasmid contains an ampicillin re-
sistance gene and colE1 replication origin. The VP6C open reading
frame was excised from the recombinant plasmid pGEM/VP6C and
inserted into SbfI and Hsp92I restriction sites of pHSVs, generating the
pHSV/HVP6C amplicon plasmid.
2.7. Cells
Vero 2-2 cells (Smith et al., 1992) were propagated in Dulbecco’s
modified Eagle medium (DMEM, Life Technologies, CA, Carlsbad, USA)
supplemented with 10% v/v fetal bovine serum (FBS. Internegocios SA,
Argentina), penicillin G (100 U/ml), streptomycin (100 μg/ml) and
Geneticin® (500 μg/ml, Life Technologies, CA, Carlsbad, USA), and
maintained at 37 °C in a 5% CO2 atmosphere.
2.8. Amplicon vector preparation
Amplicon vector stocks were prepared as previously described
(Laimbacher et al., 2012; Laimbacher and Fraefel et al., 2014; De
Oliveira et al., 2008; Saeki et al., 2001). Briefly, in order to obtain the
amplicon vector stocks, Vero 2-2 cells were co-transfected with the
amplicon plasmid, a bacterial artificial chromosome containing the
replication-competent and packaging-defective HSV-1 genome
(fHSVΔpacΔICP27), and the pEBHICP27 plasmid which provides ICP27
in trans using LipofectamineTM and PlusTM Reagent (Life Technologies,
CA, Carlsbad, USA), following manufacturer’s instructions. Seventy-two
hours post-transfection, cells were scraped off into the medium and
supernatant was recovered by centrifugation at 2000g for 5min at 4˚C.
Titers of amplicon vectors were determined in Vero 2-2 cells, by scoring
the number of GFP positive cells under a fluorescence microscope (Axio
Observer inverted microscope; Zeiss AG, Feldbach, Switzerland), after
24 h post-transduction. Titer was expressed as transducing units per
milliliter (TU/ml).
2.9. Immunofluorescence assays
Vero 2-2 cells were grown on 12-mm glass coverslips in 24-well cell
culture plates and transduced with HSV-hVP6C amplicon vector at a
50–60% cell confluence with an MOI of 0.5 TU/cell. Infected and non-
infected (control) cells were washed with PBS and then incubated in
fixation solution (3.7% v/v formaldehyde in PBS) for 15min at room
temperature. After a 5-min treatment with 0.1M glycine in PBS, cells
were permeabilized with PBS-T (0.2% v/v Triton X-100 in PBS).
Blocking was performed with PBS-BSA (3% w/v bovine serum albumin
in PBS). To detect recombinant hRVC VP6 protein cells were incubated
for one h at 37 °C in a humidity chamber with anti- VP6 (Cowden
strain) rabbit IgG (kindly provided by Dr. Cohen, Virologie Moleculaire
et Structurale, Cédex, France) as primary antibody diluted in PBS-BSA
(1:400). After three washes with PBS a 1:400 dilution of goat anti-
rabbit IgG(H+ L)-Alexa Fluor 594 (Molecular Probes, Invitrogen, USA)
secondary antibody was added and incubated for one h at 37 °C in a
humidity chamber. After three washes with PBS, cell nuclei were
stained with DAPI (1 μg/ml in PBS; Roche, Switzerland). After the
washing steps, coverslips were mounted in Glycergel (Dako
Cytomation, Denmark) containing 25mg/ml DABCO (Sigma-Aldrich)
to retard discoloration. Samples were analyzed using a confocal laser-
scanning microscope SP2 (Leica Microsystems, Wetzlar, Germany, 63
X/80 X oil objective).
For comparison purposes, the same procedure was performed by
transduction of Vero 2-2 cells with HSV-hVP6A amplicon vector (ex-
pressing VP6 protein from human group A, rotavirus strain Wa). For
hRVA VP6 detection permeabilized cells were probed with the mono-
clonal antibody 2F diluted in PBS-BSA (1:2000), followed by incubation
with Alexa Fluor 594-conjugated goat anti-mouse IgG antibody
(1:1000) (Palacios et al., 2015).
2.10. Western blot
Vero 2-2 cells and HSV-hVP6A transduced cells, were washed with
PBS, lysed with 5X Laemmli buffer, and the protein extracts were se-
parated by SDS-polyacrylamide gel electrophoresis. Proteins were
transferred onto a PVDF membrane and after blocking with PBS-T
containing 1% w/v casein (PBS-TC), probed ON at 4 °C with biotiny-
lated rabbit anti-VP6 (Cowden strain) IgG in PBS-TC (1:200). After
washing, the membrane was incubated with HRP-streptavidin (1:2500
dilution; Dako, Denmark) in PBS-TC, followed by detection with a
chemiluminescent substrate (Kalium Technologies, Bernal, Argentina)
according to manufacturer's instructions. As negative controls, un-
transduced cells and cells transduced with an unrelated amplicon vector
HSV[MSP5], coding for Anaplasma marginale MSP5 antigen were used
(Palacios et al., 2014).
2.11. Mouse immunization and sample collection
Three groups of six mice each (8-week old male BALB/c mice),
previously confirmed to be negative for anti-RV antibodies by EIA, were
immunized subcutaneously three times (on days 0, 28, and 42) using
1×106 TU of HSV-hVP6C amplicon vector per dose, PBS or HSV-EGFP
(1×106 TU) as control groups. Blood samples were collected on days
0, 28 and 42 before each immunization and a final sample was obtained
on day 56. Sera were recovered and stored individually at -20 °C until
use. All animal procedures were conducted according to the
Universidad Nacional de Quilmes Ethics Committee regulations.
2.12. EIA analysis of mouse sera
The humoral immune response was evaluated by an in-house EIA.
Briefly, capture antibody [rabbit anti-RVC VP6 (Cowden strain) serum]
was immobilized onto EIA 96-well plates overnight at 4 °C in carbonate
buffer. A previously calibrated dilution of a pool of RVC positive stool
samples (Castello et al., 2002), were incubated in PBS-TC for one h at
37 °C in a humidity chamber. Stool samples positive for RVA and ne-
gative for RVC were used to set blank. After washing three times with
PBS-T, the collected mouse sera were tested in a 1:100 dilution (in PBS-
TC), and plates were incubated for one h at 37 °C. Finally, HRP-con-
jugated goat anti-mouse IgG (DAKO, Denmark) was added to the plates
for one h at 37 °C. Plates were washed three times with PBS-T, and the
o-phenylenediamine substrate was used for detection. The reaction was
stopped after 15min with sulfuric acid, and the OD490 nm was de-
termined. The cut-off value for this assay was calculated as 0.589
OD490 nm. For titration of specific RVC IgG, sera from groups immunized
with HSV- hVP6C or HSV-EGFP were two-fold serially diluted and
evaluated as mentioned above. The titer was informed as the reciprocal
of the last positive dilution.
2.13. Statistics
Statistics were performed with GraphPad Prism software (La Jolla,
CA) and the results are expressed as the mean ± standard deviation
(SD). The statistical tests used are mentioned in the figure captions.
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3. Results
3.1. Analysis of the hRVC VP6 sequence
The complete VP6 ORF sequence was amplified by PCR, cloned into
the pGEM-T vector and its identity confirmed by sequencing. The ob-
tained 1206 bp sequence (MF422080) was compared with 66 RVC VP6
sequences available in GenBank (32 human, 30 porcine and four bo-
vine). Argentinian hRVC VP6 sequence clustered into genotype I2
(Fig. 1) with all human RVC strains (Baek et al., 2013; Jeong et al.,
2015; Stipp et al., 2015; Suzuki et al., 2014; Yamamoto et al., 2011).
The nucleotide and amino acid evolutionary divergence were ana-
lyzed by comparing the obtained VP6 sequence with available RVC VP6
sequences from human, porcine and bovine origin (Table 1). The di-
vergence was higher between the vp6 nucleotide sequences from dif-
ferent species (around 22%) while for the amino acid sequences was
around 10%. The divergence within the human strains subgroup was
lower than 3%.
3.2. Generation of HSV-hVP6C
The hRVC VP6 coding sequence was subcloned from pGEM-T into
pHSV under the control of the HSV-1 immediate-early (IE) 4/5 pro-
moter, upstream of an internal ribosomal entry site (IRES) element of
poliovirus followed by the enhanced green fluorescent protein (EGFP)
coding sequence and the SV40 polyadenylation signal (Fig. 2).
The amplicon plasmid was co-transfected together with HSV-1
helper DNA into Vero 2-2 cells, and the recombinant amplicon vector
stocks were collected 72 h post-transfection, producing a titer of
2.7× 105 TU/ml. RVC VP6 expression was evaluated by Western blot
and immunofluorescence analyses.
Western blot analysis confirmed a reactive band with the expected
molecular weight (44.7 kDa) in the protein extracts obtained from HSV-
hVP6C transduced cells (Fig. 3, lane 1) whereas no detectable reactivity
was observed in protein extracts from uninfected cells or in extracts
derived from cells infected with HSVs[MSP5] (unrelated HSV am-
plicon) (Palacios et al., 2014) (Fig. 3, lanes 2 and 3).
VP6 expression in amplicon vector-infected cells was also assessed
by immunofluorescence. As shown in Fig. 4 (Merged column, VP6C
row), the observed fluorescence pattern is mainly cytoplasmic with a
strong signal near the nucleus. For comparison purposes, the obtained
images were contrasted against images from cells transduced with a
HSV-1 amplicon vector expressing RVA VP6 protein (HSV-hVP6A). The
intracellular distribution of RVA VP6 presented a cytoplasmic fiber-like
pattern Fig. 4 (Merged column, VP6A row) (Palacios et al., 2015),
which is markedly different from that observed for RVC VP6. As ex-
pected, untransduced cells did not present any signal for VP6 or EGFP
expression.
3.3. Mouse humoral response to HSV-hVP6C
The presence of specific anti-VP6 IgG was determined by EIA in sera
obtained on days 0, 28, 42 and 56 of mice immunized subcutaneously
with HSV-hVP6C or PBS (control group). As shown in Fig. 5A, HSV-
hVP6C induced an hRVC-specific IgG response, in the absence of an
adjuvant. An increase in anti-VP6 specific IgG OD490 values was
Fig. 1. Phylogenetic dendrogram of RVC vp6 genes constructed by the neighbor-joining
method using the MEGA v6.06 software. Numbers shown at the branch nodes indicate the
bootstrap values (values< 80 were not included); the genotype is shown on the right
side. The sequence obtained in this study is (H-653-Argentina) is marked with a black line
at the right.
Table 1
Average identity in nucleotide and amino acid sequences of Argentinian hRVC VP6 and
66 humans, porcine or bovine strains.
Argentinian hVP6
sequence
Human strains
(%)
Porcine strains
(%)
Bovine Strains
(%)
Nucleotide 97.9 75.9 74.6
Amino acid 99.6 88.9 87.9
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observed for all mouse sera after the second and third immunizations,
evaluated at days 42 and 56, respectively. It is important to note that all
mice in the group responded to the immunization (data not shown). The
titer of specific IgG in the group immunized with HSV-hVP6C was
significantly higher than the titer of the control group immunized with
the empty amplicon vector (HSV-EGFP; Fig. 5B).
4. Discussion
In the present work, we constructed an HSV-1 amplicon vector en-
coding the hRVC VP6 protein. It is interesting to note that the cloned
VP6 sequence was obtained from a local circulating hRVC strain which,
when compared to other VP6 sequences, grouped with Indian, Russian
and Spanish strains, within the human clade. We also analyzed the
divergence of the obtained sequence with RVC VP6 from human, por-
cine and bovine strains. The comparison with other human strains se-
quences demonstrated a very low divergence among them (about 3%),
whereas divergence rates of about 10% were seen with their porcine
and bovine counterparts. Although the divergence between human and
porcine strains is not high, these small differences should be taken into
account when designing a VP6-based immunogen to optimize its per-
formance against hRVC.
HSV-1 based amplicon vectors have been described as efficient tools
for gene transfer because of their large transgene capacity and their
ability to efficiently transduce different mammalian cells (Santos et al.,
2007). This large transgene capacity allowed the packaging of ap-
proximately 20 copies of the transgene cassette that included not only
an hRVC VP6 coding sequence but also an IRES sequence and the EGFP
coding sequence that facilitates titration of the vector stocks and
monitoring transduced cells by fluorescence microscopy.
In this work, the VP6 protein was chosen as a model protein for the
evaluation of HSV-1 vectors against hRVC for two main reasons. The
first one, associated with the fact that VP6 protein is the most im-
munogenic and abundant in the virion; the second, in relation to what
is known about RVA. For this group, several studies have pointed out
that the VP6 protein confers protection against infection in some animal
models, despite not inducing neutralizing antibodies. In particular,
Jalilvand et al. (2015) have excellently summed up the main con-
tributions of different groups that have worked with the VP6 protein of
RVA as an immunogen. Also, recent publications have used VP6 protein
as an immunogen proposed for vaccine development against RVA fol-
lowing different strategies (Feng et al., 2017; Afchangi et al., 2017). On
the other hand, given the degree of sequence conservation observed
within the same group, VP6 is an excellent candidate for an immunogen
since it would be able to confer heterotypic protection.
Western blot analysis of protein extracts from HSV-hVP6C trans-
duced cells using specific anti-RVC VP6 (Cowden strain) IgG revealed a
unique band corresponding to the molecular weight of VP6, confirming
the expression and identity of the recombinant protein. Furthermore,
immunofluorescence analysis performed on transduced fixed cells also
confirmed VP6 expression, revealing a cytoplasmic distribution pattern
of the protein and a single perinuclear inclusion. As far as we know, this
is the first report describing the intracellular distribution of the re-
combinant hRVC VP6 protein. It is worth mentioning that the observed
protein distribution was quite different from that observed for RVA VP6
protein expressed in the same cell line following the same expression
strategy. In this case, recombinant RVA VP6 presented tubular struc-
tures within the cytoplasm, similar to that observed when is expressed
in insect cells where it can also assemble in different structures (trimers,
spheres, and tubes) in vitro, depending on the pH and ionic strength
conditions (Lepault et al., 2001). Similar results were obtained by Bugli
et al. (2014), for a RVA VP6 protein expressed in Escherichia coli. Mena
et al. (2006), confirmed the presence of tubular structures in vivo when
RVA VP6 was expressed in High Five cell line and showed that the
characteristic cytoplasmic distribution of VP6 was not due to an in-
teraction between VP6 and microtubules. With HSV-1 amplicon
strategy, we reproduced the reported tubular RVA VP6 intracellular
distribution and showed that the distribution of RVC VP6 protein is
different, which has not previously been reported.
RVA virions have been reported to be stable while RVC virions are
fragile and unstable (Esona et al., 2008). It might be interesting to in-
vestigate whether the different properties of RVA and RVC VP6 proteins
observed in HSV-1 amplicon vector transduced cells may be in some
way related to this phenomenon which is beyond the scope of the
present work.
HSV-1 based vectors have been described as promising candidates
for the design of a new generation of genetic vaccines (Cuchet et al.,
2007; Marconi et al., 2009). Notably, it has been reported that they can
elicit both cellular and humoral immune responses that, in some cases,
Fig. 2. Schematic representation of the HSV-hVP6C amplicon plasmid. The VP6 coding
sequence is cloned downstream of the HSV-1 IE4/5 promoter (IE4/5 Prom) and upstream
of a poliovirus internal ribosomal entry site (IRES), green fluorescent protein (EGFP)
coding sequences, and an SV40 polyadenylation signal (Poly A). OriS and the pac Signal
represent the HSV-1 sequences that support amplicon DNA replication and packaging into
HSV-1 particles, respectively. The ampicillin resistance gene, as well as the colE1 re-
plication origin, needed for prokaryotic propagation, are also depicted.
Fig. 3. Western blot analysis of total protein extracts. Protein suspension obtained from
HSV-hVP6C infected cells (lane 1), uninfected cells (lane 2) and cells infected with the
unrelated vector, HSVs[MSP5] (lane 3). The size of the molecular weight standards (kDa)
and the VP6 band are indicated at the left and right of the membrane, respectively.
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can persist for at least five months (D’Antuono et al., 2010; Laimbacher
et al., 2012). Despite the fact that they have several characteristics that
make them very efficient tools for delivering heterologous genes in vivo,
some disadvantages have been mentioned. In an example, their pro-
duction is based upon transfecting cells, making the scaling up process
difficult, although the amplicon titers obtained are reasonable good.
Moreover, some authors have reported some instability in the gene
expression (Sena-Esteves et al., 2000).
In this work, we analyzed the humoral immune response obtained
when recombinant HSV-1 based amplicon vectors encoding hRVC VP6
protein were inoculated in mice in the absence of adjuvants. All the
individuals within the immunized group produced specific antibodies
Fig. 4. Immunofluorescence analysis of HSV-hVP6C and HSV-hVP6A transduced cells. Vero cells were infected at an MOI of 0.1 TU/cell and, after 24 h, fixed, permeabilized, and probed
using polyclonal anti-RVC VP6 or monoclonal anti-RVA VP6 antibodies, stained with an Alexa Fluor 594-conjugated secondary antibody, and analyzed using a confocal laser-scanning
microscope. DAPI was used to visualize cell nuclei. Scale bar= 15 μm.
Fig. 5. Detection of anti-RVC IgG by EIAA. The graph shows the optical density at 490 nm (OD 490 nm) for a 1:100 dilution of mouse sera obtained at days 0, 28, 42 and 56 post-
immunization. Each bar represents the mean ± SD obtained for groups immunized with PBS, HSV-EGFP (control groups) or HSV-hVP6C. Differences were analyzed by a two-way
ANOVA followed by Tukey multiple comparisons post-test. * p < 0.05, **** p < 0.0001. B. Titer obtained for sera from groups immunized with HSV-EGFP (control group) or HSV-
hVP6C. Symbols represent the titers obtained in three independent determinations for each mouse within the group. The lines represent the mean ± SD. Statistically different according
to a non-parametric t-test (Mann Whitney), **** p < 0.0001.
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against hRVC, which markedly increased after each booster im-
munization.
Unfortunately, there is not an optimized animal model that can be
used to evaluate whether the obtained immune response is effective at
preventing hRVC infection or disease. Furthermore, a neutralization
test would not help to assess whether the generated antibodies are
capable of neutralizing viral infection, since VP6 forms the intermediate
capsid of the viral particle and RVC does not grow correctly in cell
cultures (Burns et al., 1996; Saif et al., 1988; Shinozaki et al., 1996;
Tsunemitsu et al., 1991). Burns et al. (1996) demonstrated that anti-
bodies directed against RVA VP6 are protective in vivo even though they
lack neutralizing activity. Taking into account these results and that
VP6 is the most conserved protein within RVC, the strategy proposed in
this work would be an excellent option to induce an immune response
against different hRVC strains circulating worldwide.
The low toxicity reported for these amplicon vectors, as well as their
safety since they are replicative-deficient viruses, make HSV-1 based
amplicons an interesting approach when designing an immunogen for
human group C rotavirus with prophylactic purposes.
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